Oxford Nanopore’s successful IPO is inspiring news for biotech entrepreneurs and a testament to the extraordinary vision of its founder and CEO Gordon Sanghera.
Amadeus-backed Oxford Nanopore lists successfully on the LSE
Amadeus Capital Partners invested in the DNA-sequencing company last year, and what a year it’s been! Now one of the UK’s most valuable startups, Oxford Nanopore has showed the world the value of its technology as researchers used it to characterise the Covid-19 genome and track new variants.
If you want to find out how Oxford Nanopore’s electronics-based sequencers increase the accuracy and richness of genetic data and drive down costs, leading to better research and facilitating machine learning, read Amadeus partner Andrea Traversone’s insightful blog here.
Amadeus Capital Partners is a global technology investor. Since 1997, the firm has raised over $1bn for investment and used it to back more than 130 companies. With vast experience and a great network, Amadeus’ team of investors and entrepreneurs share a passion for the transformative power of technology. We invest in consumer services, financial technology, artificial intelligence, cyber security, medical technology, digital healthcare and digital media.